ShangPharma Congratulates Morphic Therapeutic
July 1, 2016 – SHANGHAI – ShangPharma , a leading China-based pharmaceutical and biotechnology research and development platform company serving healthcare industry, congratulates Morphic Therapeutic for accomplishing $51.5 Million Series A financing to develop Next-Generation integrin therapies. Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin drugs, announced today that it has […]